Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- BSPM -31% (also determines that there is substantial doubt as to its ability to continue as a going concern)
- ZOES -12.8%, PINC -7.4%, SEAC -6.3%, TOUR -4.6%, SJM -3.3%, SVA -2.3%, AMWD -0.9%
Other news:
- XCOM -47.9% (light volume; receives notice of termination of the Master Manufacturing Agreement between the Company and NSG Technology pursuant to the default and termination provisions contained therein)
- SPHS -23.7% (Sophiris Bio to offer and sell, subject to market and other conditions, its common shares and warrants to purchase additional common shares in an underwritten public offering )
- TKAI -19.1% (to discontinue enrollment in its ongoing ARMOR2 expansion clinical trial of galeterone in metastatic castration-resistant prostate cancer patients with acquired resistance to Xtandi, will not proceed with its planned study of galeterone in mCRPC patients who rapidly progress on either enzalutamide or Zytiga)
- ROSG -12.4% ( receives notice of rescission of conditional approval from the New York State Department of Health for four of its allele-specific PCR -based assays to test for BRAF, EGFR, KRAS and NRAS mutations in various cancers)
- LPTN -11.6% ( files for $10 mln mixed shelf offering)
- COSI -10.1% ( CFO resigns effective September 23, 2016, and co terminates CEO effective immediately)
- STEM -2.2% (still checking)
- CXRX -1.3% (Concordia discloses that Chairman and Chief Executive Officer Mark Thompson was notified earlier today of the sale of 505k of his shares as part of a margin call)
Analyst comments:
- LOGI -2.8% (downgraded to Neutral from Buy at UBS)
- OAS -2.4% (downgraded to Market Perform from Outperform at BMO Capital)
- KR -1% (downgraded to Neutral from Buy at Cleveland Research)